Announcement

Collapse
No announcement yet.

Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States

    Summary of recent changes (last updated February 10, 2021):
    • New recommendations for preventing, reporting, and managing mRNA COVID-19 vaccine administration errors (Appendix A).
    • Clarification on contraindications and precautions. Persons with a known (diagnosed) allergy to PEG, another mRNA vaccine component, or polysorbate, have a contraindication to vaccination. Persons with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is PEG, another mRNA vaccine component or polysorbate, but in whom it is unknown which component elicited the immediate allergic reaction have a precaution to vaccination.
    • Updated information on delayed, local injection-site reactions after the first mRNA vaccine dose. These reactions are neither a contraindication or precaution to the second dose.
    • Updated quarantine recommendations for vaccinated persons. Fully vaccinated persons who meet criteria will no longer be required to quarantine following an exposure to someone with COVID-19. Additional considerations for patients and residents in healthcare settings are provided.
    • Additional information and updated recommendations for testing for TB infection. TB testing can be done before or at the same time as mRNA COVID-19 vaccination, or otherwise delayed for ≥4 weeks after the completion of mRNA COVID-19 vaccination.
    https://www.cdc.gov/vaccines/covid-1...derations.html

Working...
X